Skip to content
2000
Volume 18, Issue 6
  • ISSN: 1573-3998
  • E-ISSN: 1875-6417

Abstract

Diabetes mellitus is an ailment that affects a large number of individuals worldwide and its pervasiveness has been predicted to increase later on. Every year, billions of dollars are spent globally on diabetes-related health care practices. Contemporary hyperglycemic therapies to rationalize Type 2 Diabetes Mellitus (T2DM) mostly involve pathways that are insulin-dependent and lack effectiveness as the pancreas’ β-cell function declines more significantly. Homeostasis via kidneys emerges as a new and future strategy to minimize T2DM complications. This article covers the reabsorption of glucose mechanism in the kidneys, the functional mechanism of various Sodium- Glucose Cotransporter 2 (SGLT2) inhibitors, their structure and driving profile, and a few SGLT2 inhibitors now accessible in the market as well as those in different periods of advancement. The advantages of SGLT2 inhibitors are dose-dependent glycemic regulation changes with a significant reduction both in the concentration of HbA1c and body weight clinically and statistically. A considerable number of SGLT2 inhibitors have been approved by the FDA, while a few others, still in preliminaries, have shown interesting effects.

Loading

Article metrics loading...

/content/journals/cdr/10.2174/1573399817666210917122745
2022-07-01
2025-07-04
Loading full text...

Full text loading...

/content/journals/cdr/10.2174/1573399817666210917122745
Loading

  • Article Type:
    Review Article
Keyword(s): dapagliflozin; diabetes mellitus; glucose; hypoglycemia; phlorizin; SGLT2 Inhibitors
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test